{"id":4417,"date":"2019-03-26T05:11:06","date_gmt":"2019-03-26T05:11:06","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4417"},"modified":"2019-11-12T15:29:11","modified_gmt":"2019-11-12T15:29:11","slug":"um-estudo-do-plx8394-como-agente-unico-em-pacientes-com-tumores-solidos-avancados-nao-ressecaveis","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/pt\/study_trials\/a-study-of-plx8394-as-a-single-agent-in-patients-with-advanced-unresectable-solid-tumors\/","title":{"rendered":"Um estudo sobre o PLX8394 como agente \u00fanico em pacientes com tumores s\u00f3lidos avan\u00e7ados e inoper\u00e1veis"},"content":{"rendered":"<p><strong>Objetivo do estudo:<\/strong>&nbsp; O objetivo deste estudo cl\u00ednico \u00e9 investigar como o PLX8394 pode afetar as c\u00e9lulas cancerosas com muta\u00e7\u00f5es no gene BRAF. O PLX8394 foi desenvolvido para bloquear muta\u00e7\u00f5es no BRAF. Essas muta\u00e7\u00f5es podem causar c\u00e2ncer e o crescimento das c\u00e9lulas cancerosas.\u00a0 Ao bloquear essas muta\u00e7\u00f5es, o medicamento pode destruir as c\u00e9lulas cancerosas portadoras da muta\u00e7\u00e3o e\/ou impedir o crescimento do tumor.<\/p>\n<p><strong>Patrocinador:<\/strong>&nbsp; Plexxikon<\/p>\n<p><strong>Informa\u00e7\u00f5es de contato para o per\u00edodo de teste:<\/strong>&nbsp; Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org ou Filip Janku; 713-563-1930; FJanku@mdanderson.org<\/p>\n<p><strong>Envolvimento solicitado do paciente:<\/strong>&nbsp; Pacientes com ECD com mais de 18 anos de idade.<\/p>\n<p><strong>Centros conhecidos que aceitam pacientes com ECD no estudo:<\/strong>&nbsp; MD Anderson, Houston, TX<\/p>\n<p><strong>Identificador do ClinicalTrials.gov:<\/strong>&nbsp; NCT02428712<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; The goal of this clinical research study is to learn how PLX8394 may affect cancer cells with mutations in the gene BRAF.&nbsp; PLX8394 is designed to block mutations [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4417","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials\/4417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/media?parent=4417"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials_cat?post=4417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}